CY1113341T1 - Ρυθμιστες υποδοχεα ανδρογονου τετραϋδροκυκλοπεντα[β]ινδολιο - Google Patents

Ρυθμιστες υποδοχεα ανδρογονου τετραϋδροκυκλοπεντα[β]ινδολιο

Info

Publication number
CY1113341T1
CY1113341T1 CY20121101095T CY121101095T CY1113341T1 CY 1113341 T1 CY1113341 T1 CY 1113341T1 CY 20121101095 T CY20121101095 T CY 20121101095T CY 121101095 T CY121101095 T CY 121101095T CY 1113341 T1 CY1113341 T1 CY 1113341T1
Authority
CY
Cyprus
Prior art keywords
tetrahydrocyclops
indolio
retractors
compound
formula
Prior art date
Application number
CY20121101095T
Other languages
Greek (el)
English (en)
Inventor
Prabhakar Kondaji Jadhav
Venkatesh Krishnan
Euibong Jemes Kim
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1113341T1 publication Critical patent/CY1113341T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/94[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20121101095T 2008-05-16 2012-11-14 Ρυθμιστες υποδοχεα ανδρογονου τετραϋδροκυκλοπεντα[β]ινδολιο CY1113341T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5372208P 2008-05-16 2008-05-16
EP09747531A EP2297100B1 (en) 2008-05-16 2009-05-14 Tetrahydrocyclopenta[b]indole androgen receptor modulators

Publications (1)

Publication Number Publication Date
CY1113341T1 true CY1113341T1 (el) 2016-06-22

Family

ID=40847864

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101095T CY1113341T1 (el) 2008-05-16 2012-11-14 Ρυθμιστες υποδοχεα ανδρογονου τετραϋδροκυκλοπεντα[β]ινδολιο

Country Status (18)

Country Link
US (1) US8486943B2 (cg-RX-API-DMAC7.html)
EP (1) EP2297100B1 (cg-RX-API-DMAC7.html)
JP (1) JP5603327B2 (cg-RX-API-DMAC7.html)
KR (1) KR101278788B1 (cg-RX-API-DMAC7.html)
CN (1) CN102026974B (cg-RX-API-DMAC7.html)
AU (1) AU2009246348B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0912394A2 (cg-RX-API-DMAC7.html)
CA (1) CA2724629C (cg-RX-API-DMAC7.html)
CY (1) CY1113341T1 (cg-RX-API-DMAC7.html)
DK (1) DK2297100T3 (cg-RX-API-DMAC7.html)
EA (1) EA019713B1 (cg-RX-API-DMAC7.html)
ES (1) ES2396612T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120917T1 (cg-RX-API-DMAC7.html)
MX (1) MX2010012436A (cg-RX-API-DMAC7.html)
PL (1) PL2297100T3 (cg-RX-API-DMAC7.html)
PT (1) PT2297100E (cg-RX-API-DMAC7.html)
SI (1) SI2297100T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009140448A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009105214A2 (en) 2008-02-22 2009-08-27 Radius Health, Inc. Selective androgen receptor modulators
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
EP3106159A1 (en) 2010-05-12 2016-12-21 Radius Health, Inc. Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
FI3122426T3 (fi) 2014-03-28 2023-03-31 Univ Duke Rintasyövän hoitaminen käyttäen selektiivisiä estrogeenin reseptorin modulaattoreita
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
EP3474841B1 (en) 2016-06-22 2022-03-16 Ellipses Pharma Ltd Ar+ breast cancer treatment methods
US20180185347A1 (en) * 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
LT3565542T (lt) 2017-01-05 2024-07-10 Radius Pharmaceuticals, Inc. Polimorfinės rad1901-2hcl formos
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ,インコーポレイテッド Rad1901-2hclの多形形態
KR20210127961A (ko) 2019-02-12 2021-10-25 래디어스 파마슈티컬스, 인코포레이티드 방법 및 화합물
EP4096660A1 (en) * 2020-01-27 2022-12-07 EirGen Pharma Ltd. Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease
US20230255933A1 (en) * 2020-07-06 2023-08-17 Crescenta Biosciences Antiviral use of fabp4 modulating compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
JP2005527464A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー sPLA2インヒビターとしてのシクロヘプタBインドール誘導体
DE10164564B4 (de) 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
EP1505061A4 (en) 2002-05-16 2007-08-22 Shionogi & Co CONNECTION WITH PGD-2 RECEPTOR ANTAGONISM
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP2007526304A (ja) 2004-03-03 2007-09-13 イーライ リリー アンド カンパニー 二環式置換インドール誘導体ステロイドホルモン核内受容体モジュレータ
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
TW200640931A (en) * 2005-02-17 2006-12-01 Wyeth Corp Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
WO2007002181A2 (en) * 2005-06-24 2007-01-04 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm)
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators

Also Published As

Publication number Publication date
ES2396612T3 (es) 2013-02-22
AU2009246348B2 (en) 2012-04-12
AU2009246348A8 (en) 2010-12-16
EP2297100A1 (en) 2011-03-23
US8486943B2 (en) 2013-07-16
WO2009140448A8 (en) 2010-01-07
EA201071317A1 (ru) 2011-06-30
PL2297100T3 (pl) 2013-03-29
CA2724629A1 (en) 2009-11-19
DK2297100T3 (da) 2012-12-17
AU2009246348A1 (en) 2009-11-19
KR20100132551A (ko) 2010-12-17
KR101278788B1 (ko) 2013-06-25
EP2297100B1 (en) 2012-10-31
US20110039855A1 (en) 2011-02-17
EA019713B1 (ru) 2014-05-30
JP5603327B2 (ja) 2014-10-08
PT2297100E (pt) 2013-01-24
MX2010012436A (es) 2010-12-06
JP2011520903A (ja) 2011-07-21
WO2009140448A1 (en) 2009-11-19
CA2724629C (en) 2014-08-19
CN102026974A (zh) 2011-04-20
SI2297100T1 (sl) 2013-02-28
HRP20120917T1 (hr) 2012-12-31
CN102026974B (zh) 2013-08-28
BRPI0912394A2 (pt) 2016-07-26

Similar Documents

Publication Publication Date Title
CY1113341T1 (el) Ρυθμιστες υποδοχεα ανδρογονου τετραϋδροκυκλοπεντα[β]ινδολιο
CY1112284T1 (el) Ενωσεις τετραϋδροκυκλοπεντα[β] ινδολιου ως ρυθμιστες υποδοχεων ανδρογονων
CY1121858T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτες και μεθοδοι χρησης αυτων
CY1108690T1 (el) Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων
ATE457979T1 (de) Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate
CY1119176T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
CY1118700T1 (el) Συνδυασμοι φαρμακων για τη θεραπευτικη αντιμετωπιση της μυϊκης δυστροφιας duchenne
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
PH12014500386A1 (en) Combination treatment for hepatitis c
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
EA200970928A1 (ru) Антагонисты рецептора гонадотропин-рилизин-фактора и способы их применения
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
CY1124301T1 (el) Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων
EA201170004A1 (ru) Использование антагонистов h4-гистаминовых рецепторов для лечения послеоперационных спаек
CY1115153T1 (el) Μεθοδοι για την αγωγη δερματολογικων διαταραχων
DOP2009000117A (es) Compuestos de tetrahidrociclopenta[b]indol como moduladores del receptor de andrógenos
CY1115482T1 (el) Πολυκυκλικοι ανταγωνιστες υποδοχεων λυσοφωσφατιδικου οξεος
CY1117266T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντι-καρκινικοι παραγοντες
CY1113374T1 (el) Ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις